双语新闻：美国公司计划对脑机设备进行重大人体测试
A U.S.-based developer of a brain-computer implant is reportedly preparing to carry out major testing of its device on humans.
据报道，一家总部位于美国的脑机植入物开发商正准备在人体上对其设备进行重大测试。
The company is called Synchron. The Reuters news agency reported that Synchron recently launched on online system that permits patients to express interest in taking part in a large research study, or trial.
该公司名为Synchron。路透社报道称，Synchron最近推出了一个在线系统，允许患者表达参与大型研究或试验的兴趣。
The company has also been in contact with more than 100 research centers that want to support the study, Synchron chief executive Thomas Oxley told Reuters.
Synchron首席执行官Thomas Oxley告诉路透社，该公司还与100多个希望支持这项研究的研究中心进行了联系。
Synchron's device is known as a brain-computer interface. It is designed to treat individuals who experience paralysis caused by injury or disease. The device contains a small computer built to electronically communicate with the brain.
Synchron的设备被称为脑机接口。它旨在治疗因受伤或疾病而导致瘫痪的患者。该设备包含一台小型计算机，用于与大脑进行电子通信。
The first tests aim to use the brain-computer interface to process brain signals to help paralyzed patients type on a computer.
第一项测试旨在使用脑机接口处理大脑信号，帮助瘫痪患者在电脑上打字。
Synchron's interface is similar to a device currently being tested by its American competitor, Neuralink. One difference is that Neuralink's device is designed to be implanted inside the skull.
Synchron的接口类似于其美国竞争对手Neuralink目前正在测试的设备。一个不同之处在于Neuralink的装置被设计成植入头骨内部。
Synchron's device uses a less invasive implant method known as endovascular. The company says this involves a vein carrying the device into a part of the brain known as the motor cortex. This part of the brain produces signals to direct body movements.
Synchron的设备使用了一种被称为血管内植入的微创植入方法。该公司表示，这涉及到一条将设备携带到大脑运动皮层的静脉。大脑的这一部分产生信号来指导身体运动。
Synchron is farther along in the development of its implant than Neuralink, Reuters reports. Neuralink's progress has mainly been announced by company chief Elon Musk on the X social media service that he owns. So far, Neuralink has said its device has been implanted in one paralyzed patient.
据路透社报道，Synchron在植入物的开发方面比Neuralink走得更远。Neuralink的进展主要是由公司首席执行官埃隆·马斯克在他拥有的X社交媒体服务上宣布的。到目前为止，Neuralink表示，其设备已植入一名瘫痪患者体内。
Testing implants in patients with brain damage can be difficult. This is because an individual's brain may be so severely damaged that there is not effective signaling to record.
在脑损伤患者身上测试植入物可能很困难。这是因为一个人的大脑可能受到严重损伤，以至于没有有效的信号记录。
Synchron's Oxley said the U.S. Food and Drug Administration (FDA) asked his company to test stroke patients using a non-invasive method to see if they would be good implant candidates.
Synchron的Oxley表示，美国食品药品监督管理局（FDA）要求他的公司使用非侵入性方法对中风患者进行测试，看看他们是否是好的植入物候选者。
In 2020, Synchron said experiments involving paralyzed patients in Australia found the individuals could use its device to type letters into a computer at a higher rate than in earlier studies.
Synchron表示，2020年，在澳大利亚对瘫痪患者进行的实验发现，这些人可以使用其设备向计算机输入字母的速度比早期研究中的速度更高。
Synchron received U.S. approval in July 2021 to carry out early testing. It has implanted its devices in six patients so far. Tests involving four patients in Australia showed no serious side effects, the company has reported.
Synchron于2021年7月获得美国批准进行早期测试。到目前为止，该公司已经为六名患者植入了该设备。该公司报告称，在澳大利亚对四名患者进行的测试显示没有严重的副作用。
Synchron says it will be examining data from its current testing to prepare for the larger study. The company must still receive FDA approval to move forward with the new study.
Synchron表示，它将检查目前测试的数据，为更大规模的研究做准备。该公司仍必须获得美国食品药品监督管理局的批准才能推进这项新研究。
Several U.S. hospitals have cooperated with Synchron on its current testing program. These include Mount Sinai in New York, the University at Buffalo Neurosurgery and the University of Pittsburgh Medical Center (UPMC). The company has said it hopes to involve these same medical centers in the larger trial.
几家美国医院已经与Synchron就其目前的检测项目进行了合作。其中包括纽约西奈山、布法罗大学神经外科和匹兹堡大学医学中心（UPMC）。该公司表示，希望让这些医疗中心参与更大规模的试验。
Dr. David Lacomis is chief of UPMC's Neuromuscular Division. He told Reuters his team is still involved in the current testing program and said "the study is going well."
David Lacomis博士是UPMC神经肌肉部门的负责人。他告诉路透社，他的团队仍在参与目前的测试项目，并表示“研究进展顺利。”
The Department of Neurosurgery in the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo has two patients in the current test program.
布法罗大学雅各布斯医学与生物医学科学学院神经外科有两名患者参加了目前的测试项目。
The head of that effort is department chief Dr. Elad Levy. He told Reuters, "the first and only stroke patient" is taking part in the study. Levy said he feels that is important because this is a large population that might see improvements from Synchron's device.
这项工作的负责人是部门主任Elad Levy博士。他告诉路透社，“第一位也是唯一一位中风患者”正在参与这项研究。Levy说，他觉得这很重要，因为这是一个庞大的群体，可能会看到Synchron设备的改进。
He added that he was hopeful and excited about the new research and future deployment of the technology.
他补充说，他对这项技术的新研究和未来部署充满希望和兴奋。
据报道，一家总部位于美国的脑机植入物开发商正准备在人体上对其设备进行重大测试。
The company is called Synchron. The Reuters news agency reported that Synchron recently launched on online system that permits patients to express interest in taking part in a large research study, or trial.
该公司名为Synchron。路透社报道称，Synchron最近推出了一个在线系统，允许患者表达参与大型研究或试验的兴趣。
The company has also been in contact with more than 100 research centers that want to support the study, Synchron chief executive Thomas Oxley told Reuters.
Synchron首席执行官Thomas Oxley告诉路透社，该公司还与100多个希望支持这项研究的研究中心进行了联系。
Synchron's device is known as a brain-computer interface. It is designed to treat individuals who experience paralysis caused by injury or disease. The device contains a small computer built to electronically communicate with the brain.
Synchron的设备被称为脑机接口。它旨在治疗因受伤或疾病而导致瘫痪的患者。该设备包含一台小型计算机，用于与大脑进行电子通信。
The first tests aim to use the brain-computer interface to process brain signals to help paralyzed patients type on a computer.
第一项测试旨在使用脑机接口处理大脑信号，帮助瘫痪患者在电脑上打字。
Synchron's interface is similar to a device currently being tested by its American competitor, Neuralink. One difference is that Neuralink's device is designed to be implanted inside the skull.
Synchron的接口类似于其美国竞争对手Neuralink目前正在测试的设备。一个不同之处在于Neuralink的装置被设计成植入头骨内部。
Synchron's device uses a less invasive implant method known as endovascular. The company says this involves a vein carrying the device into a part of the brain known as the motor cortex. This part of the brain produces signals to direct body movements.
Synchron的设备使用了一种被称为血管内植入的微创植入方法。该公司表示，这涉及到一条将设备携带到大脑运动皮层的静脉。大脑的这一部分产生信号来指导身体运动。
Synchron is farther along in the development of its implant than Neuralink, Reuters reports. Neuralink's progress has mainly been announced by company chief Elon Musk on the X social media service that he owns. So far, Neuralink has said its device has been implanted in one paralyzed patient.
据路透社报道，Synchron在植入物的开发方面比Neuralink走得更远。Neuralink的进展主要是由公司首席执行官埃隆·马斯克在他拥有的X社交媒体服务上宣布的。到目前为止，Neuralink表示，其设备已植入一名瘫痪患者体内。
Testing implants in patients with brain damage can be difficult. This is because an individual's brain may be so severely damaged that there is not effective signaling to record.
在脑损伤患者身上测试植入物可能很困难。这是因为一个人的大脑可能受到严重损伤，以至于没有有效的信号记录。
Synchron's Oxley said the U.S. Food and Drug Administration (FDA) asked his company to test stroke patients using a non-invasive method to see if they would be good implant candidates.
Synchron的Oxley表示，美国食品药品监督管理局（FDA）要求他的公司使用非侵入性方法对中风患者进行测试，看看他们是否是好的植入物候选者。
In 2020, Synchron said experiments involving paralyzed patients in Australia found the individuals could use its device to type letters into a computer at a higher rate than in earlier studies.
Synchron表示，2020年，在澳大利亚对瘫痪患者进行的实验发现，这些人可以使用其设备向计算机输入字母的速度比早期研究中的速度更高。
Synchron received U.S. approval in July 2021 to carry out early testing. It has implanted its devices in six patients so far. Tests involving four patients in Australia showed no serious side effects, the company has reported.
Synchron于2021年7月获得美国批准进行早期测试。到目前为止，该公司已经为六名患者植入了该设备。该公司报告称，在澳大利亚对四名患者进行的测试显示没有严重的副作用。
Synchron says it will be examining data from its current testing to prepare for the larger study. The company must still receive FDA approval to move forward with the new study.
Synchron表示，它将检查目前测试的数据，为更大规模的研究做准备。该公司仍必须获得美国食品药品监督管理局的批准才能推进这项新研究。
Several U.S. hospitals have cooperated with Synchron on its current testing program. These include Mount Sinai in New York, the University at Buffalo Neurosurgery and the University of Pittsburgh Medical Center (UPMC). The company has said it hopes to involve these same medical centers in the larger trial.
几家美国医院已经与Synchron就其目前的检测项目进行了合作。其中包括纽约西奈山、布法罗大学神经外科和匹兹堡大学医学中心（UPMC）。该公司表示，希望让这些医疗中心参与更大规模的试验。
Dr. David Lacomis is chief of UPMC's Neuromuscular Division. He told Reuters his team is still involved in the current testing program and said "the study is going well."
David Lacomis博士是UPMC神经肌肉部门的负责人。他告诉路透社，他的团队仍在参与目前的测试项目，并表示“研究进展顺利。”
The Department of Neurosurgery in the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo has two patients in the current test program.
布法罗大学雅各布斯医学与生物医学科学学院神经外科有两名患者参加了目前的测试项目。
The head of that effort is department chief Dr. Elad Levy. He told Reuters, "the first and only stroke patient" is taking part in the study. Levy said he feels that is important because this is a large population that might see improvements from Synchron's device.
这项工作的负责人是部门主任Elad Levy博士。他告诉路透社，“第一位也是唯一一位中风患者”正在参与这项研究。Levy说，他觉得这很重要，因为这是一个庞大的群体，可能会看到Synchron设备的改进。
He added that he was hopeful and excited about the new research and future deployment of the technology.
他补充说，他对这项技术的新研究和未来部署充满希望和兴奋。
